Literature DB >> 16488077

Effects of bone sialoprotein on pancreatic cancer cell growth, invasion and metastasis.

Hany Kayed1, Jörg Kleeff, Shereen Keleg, Klaus Felix, Thomas Giese, Martin R Berger, Markus W Büchler, Helmut Friess.   

Abstract

Bone sialoprotein (BSP) is an acidic glycoprotein that plays an important role in cancer cell growth, migration and invasion. The expression, localization and possible function of BSP in chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC) were analyzed by QRT-PCR, laser capture microdissection, DNA microarray analysis, immunoblotting, radioimmunoassays and immunohistochemistry as well as cell growth, invasion, scattering, and adhesion assays. BSP mRNA was detected in 40.7% of normal, in 80% of CP and in 86.4% of PDAC samples. The median BSP mRNA levels were 6.1 and 0.9copies/microl cDNA in PDAC and CP tissues, respectively, and zero copies/microl cDNA in normal pancreatic tissues. BSP was weakly present in the cytoplasm of islet cells and ductal cells in 20% of normal pancreatic tissues. BSP was localized in the tubular complexes of both CP and PDAC, as well as in pancreatic cancer cells. Five out of 8 pancreatic cancer cell lines expressed BSP mRNA. Recombinant BSP (rBSP) inhibited Capan-1 and SU8686 pancreatic cancer cell growth, with a maximal effect of -46.4+/-12.0% in Capan-1 cells and -45.7+/-14.5% in SU8686 cells. rBSP decreased the invasion of SU8686 cells by -59.1+/-11.2% and of Capan-1 cells by -13.3+/-3.8% (P<0.05), whereas it did not affect scattering or adhesion of both cell lines. In conclusion, endogenous BSP expression levels in pancreatic cancer cells and low to absent BSP expression in the surrounding stromal tissue elements may indirectly act to enhance the proliferation and invasion of pancreatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16488077     DOI: 10.1016/j.canlet.2006.01.002

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

Review 1.  SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.

Authors:  Ferda Kaleağasıoğlu; Martin R Berger
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

2.  Correlation between calcification and bone sialoprotein and osteopontin in papillary thyroid carcinoma.

Authors:  Gang Wu; Jing-Jing Guo; Zhen-Yu Ma; Jie Wang; Zhong-Wen Zhou; Yi Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 3.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.

Authors:  Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

4.  Gene expression profiles associated with advanced pancreatic cancer.

Authors:  Domenico Campagna; Leslie Cope; Sindhu S Lakkur; Clark Henderson; Daniel Laheru; Christine A Iacobuzio-Donahue
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

5.  Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma.

Authors:  Sven H Loosen; Pia Hoening; Niklas Puethe; Mark Luedde; Martina Spehlmann; Tom F Ulmer; David V Cardenas; Sanchari Roy; Frank Tacke; Christian Trautwein; Ulf P Neumann; Tom Luedde; Christoph Roderburg
Journal:  Sci Rep       Date:  2019-02-06       Impact factor: 4.379

6.  High bone sialoprotein (BSP) expression correlates with increased tumor grade and predicts a poorer prognosis of high-grade glioma patients.

Authors:  Tao Xu; Rong Qin; Jinxu Zhou; Yong Yan; Yicheng Lu; Xiaoping Zhang; Da Fu; Zhongwei Lv; Weiqing Li; Chunyan Xia; Guohan Hu; Xuehua Ding; Juxiang Chen
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

7.  Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer.

Authors:  H Kayed; X Jiang; S Keleg; R Jesnowski; T Giese; M R Berger; I Esposito; M Löhr; H Friess; J Kleeff
Journal:  Br J Cancer       Date:  2007-09-18       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.